secwatch.observer — SEC 8-K summary
======================================

Issuer:     Passage BIO, Inc. (PASG)
CIK:        0001787297
Form:       8-K
Filed at:   2023-07-31T23:59:59+00:00
Accession:  0001104659-23-085580
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Passage Bio board change: director resigns, new director Dolan Sondhi appointed
-------------------------------------------------------------------------------

- Thomas Woiwode resigned from Board and Compensation Committee effective July 26, 2023; no disagreement cited.
- Board appointed Dr. Dolan Sondhi as Class II director effective July 27, 2023, filling a vacancy.
- Dr. Sondhi is Professor of Research in Genetic Medicine at Weill Cornell, with gene therapy expertise.
- Received non-incentive stock options for 48,000 shares vesting over three years under 2020 Equity Plan.
- Also appointed to the Nominating and Corporate Governance Committee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787297/000110465923085580/0001104659-23-085580-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787297/000110465923085580/tm2322324d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-085580

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer